Why I’d sell Purplebricks Group plc to buy this growth stock

Purplebricks Group plc (LON: PURP) could have flown too far too soon, but here’s a growth candidate that’s yet to soar.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Purplebricks (LSE: PURP) has been very popular with investors of late. In fact, thanks to the company’s excellent advertising (I see the ‘commisery’ campaign as particularly compelling), almost everybody has heard of it.

But though that’s highly desirable from a marketing perspective, it can be anathema to those trying to find a bargain share. And I feel sure that this very high public profile has drawn far more investors in to buying the shares than we’d otherwise see, and that has pushed prices up to levels that I find scary.

Do you remember online fashion retailer ASOS? Its shares peaked quickly too, but they crashed and they’re still lower today than back in February 2014.

Where’s the profit?

There are no Purplebricks profits expected before 2019, and even then the City is only predicting a modest pre-tax profit of £6.6m — with the shares at 371p today, we’re looking at a forward P/E of 206, two years out. And that’s after the price has fallen back a bit — at August’s peak of 525p, that P/E stood at nearly 300.

Now, I know a huge P/E in the first profitable year can be misleading, but I turn to my second biggest concern — how much of a barrier to entry for an online company is there? With relatively little in the way of material infrastructure needed to set up a similar operation, I don’t actually see a lot — there are no expensive warehouses or distribution chains like ASOS needs (and even there, Boohoo.Com is hot on its heels).

Two more years before any profit, and a whole real estate sector that’s surely looking at the model and planning some moves.

Good company, first-mover, great marketing, too expensive.

Pharma upstart

Allergy Therapeutics (LSE: AGY) is a pharmaceutical group specialising in allergy vaccines, and it released full-year results Thursday. 

Earnings have been a bit erratic of late, to say the least. But there are some core trends that really make me think I’m looking at a company with a focus on the long term and not on grabbing short-term attention — in particular, the firm has achieved a “10% compound annual growth in net sales over 18 years.

The year to June 2017 resulted in a 32% rise in revenue (15% at constant currency) leading to a 72% hike in operating profit, and a 13% gain in European market share.

Chief executive Manuel Llobet spoke of “continuing growth and progress on our pipeline“, saying he expects “further good progress in the coming year.

There’s some investor sentiment getting behind Allergy Therapeutics too, with the share price having gained 64% in the past 12 months to today’s 32.75p. Invesco Perpetual, formerly managed by Neil Woodford, owns almost 6% of the stock, and I see that as an important vote of confidence.

The risk?

A possible downside to an investment here is that it would not expose us to the same diversification that is offered by many of the company’s fellows in the pharmaceuticals sector. And with the chance that big investments in narrowly-focused research areas can come to nought being sizeable, I don’t want to underestimate that risk.

But being focused on the specific field of allergy research (which is addressing an increasing problem in the 21st century), the potential rewards could be high.

On balance, I see Allergy Therapeutics as a risk worth taking.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended ASOS. The Motley Fool UK has recommended boohoo.com. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

A FTSE 100 share that could create generational wealth

Investing in FTSE shares can help individuals pass down a significant chunk of cash to their children and grandchildren, data…

Read more »

Investing Articles

Here’s what the BT share price could mean for passive income investors

The BT share price has been falling for years, but that might be about to change. And dividends could be…

Read more »

Investing Articles

At £4.76, is the Aviva share price a steal? Here’s what the charts say!

Aviva has outperformed the Footsie over the last year. But is there still value in its share price? This Fool…

Read more »

Photo of a man going through financial problems
Investing Articles

Does a 43% price drop make this undervalued UK stalwart one of the best cheap shares to buy now?

After losing a third of its value of the past five years, this might be one of the most undervalued…

Read more »

Businessman use electronic pen writing rising colorful graph from 2023 to 2024 year of business planning and stock investment growth concept.
Investing Articles

My top 3 picks today for a £20,000 Stocks and Shares ISA

Here are three very different investments to consider for a Stocks and Shares ISA, covering both the UK and US…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The Darktrace share price has been surging — and it could climb higher

I think the Darktrace share price could have more room to run. Despite the competitive AI industry, the firm looks…

Read more »

Young Black man sat in front of laptop while wearing headphones
Investing Articles

With its 7% dividend, should I be watching the Aviva share price?

Dividend investors will struggle to find many companies with a yield above 7%, so should the Aviva share price be…

Read more »

Investing Articles

Could this be one of the FTSE 100’s best cheap dividend shares?

Looking for the best dividend growth shares to buy? Our writer Royston Wild thinks this FTSE 100 housebuilder might well…

Read more »